PeptideVS
Weight Loss
Phase 2
Evidence: Low / Preclinical

AOD-9604

Also known as: Advanced Obesity Drug, Tyr-hGH Fragment 176-191

Overview
Fat loss and metabolism enhancement

AOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sugar and insulin sensitivity. Despite promising early research, Phase 2 clinical trials failed to demonstrate significant weight loss compared to placebo, and it was never approved by the FDA.

Mechanism of Action

Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1

Dosage Information
ParameterDetail
AdministrationSubcutaneous injection
Typical Dose300mcg daily
FrequencyDaily
Side Effects
Reported adverse effects from clinical data and post-market surveillance

Common Side Effects

Injection site reactions
Headache
Chest tightness (rare)

Serious Side Effects

Unknown long-term effects
Potential interactions with growth hormone pathways
!Contraindications
Do not use this peptide if any of the following apply
  • Pregnancy
  • Cancer
  • Children
Clinical Evidence

Evidence Quality

Low / Preclinical

Clinical Trial Phase

Phase 2

View Key Study
Cost Comparison
Estimated monthly costs compared to similar peptides
PeptideMonthly CostFDA Status
AOD-9604$30 - $60/mo
Phase 2
Semaglutide$1000 - $1400/mo
FDA Approved
Tirzepatide$1100 - $1500/mo
FDA Approved
Retatrutide$1200 - $1500/mo
Phase 3

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.